Phase III
AbbVie announced that the Phase III MERU trial evaluating Rova-T as first-line maintenance therapy for advanced small-cell lung cancer, failed to demonstrate a survival benefit following a pre-planned interim analysis.
The trials met the primary endpoints, with ofatumumab demonstrating a highly significant and clinically meaningful decrease in the number of confirmed relapses. The trials also hit key secondary endpoints, delaying the time to confirmed disability progression.
AstraZeneca announced positive results from the Phase III ETHOS trial for triple-combination therapy PT010 in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
The TULIP 2 trial was the second Phase III trial that assessed the safety and efficacy of anifrolumab as a treatment for adults with moderate-to-severe SLE.
Breztri Aerosphere is a triple combination drug of budesonide, glycopyrronium and formoterol fumarate.
Inclisiran is a PCSK9 inhibitor, a class of anti-cholesterol medications used to treat patients who don’t respond to statins.
The investigational JAK inhibitor has hit the mark in three late-stage studies, with readouts from two more late-stage trials expected later this year.
Retrophin, Inc. announced that the Phase 3 FORT Study evaluating the safety and efficacy of fosmetpantotenate compared to placebo in patients with pantothenate kinase-associated neurodegeneration did not meet its primary endpoint and did not demonstrate a difference between treatment groups.
Biopharma companies large and small are involved in numerous clinical trials. Here’s a look at some of the top stories from last week.
Shares of Retrophin have plunged more than 24% in premarket trading after the San Diego-based company announced its Phase III treatment for pantothenate kinase-associated neurodegeneration did not stack up against placebo.
PRESS RELEASES